poisar

Stocks · News reference

MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'

BenzingaVandana Singh

MDxHealth reports Q2 sales growth, mixed earnings and reaffirmed 2026 revenue guidance as tissue test volumes rise.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading